Company Encyclopedia
View More
name
Neumora Therapeutics
NMRA.US
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease. In addition, the company’s preclinical phase product includes NMRA-NMDA and NMRA-M4R for the treatment of Schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson’s disease.
4.081 T
NMRA.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    H.C. Wainwright Sticks to Its Buy Rating for Neumora Therapeutics, Inc. (NMRA)

    H.C. Wainwright has maintained a Buy rating for Neumora Therapeutics, Inc. (NMRA) with a price target of $18.00, according to analyst Douglas Tsao. Tsao, who focuses on the Healthcare sector, has an average return of 22.0% and a 53.85% success rate. Additionally, Needham's Ami Fadia also issued a Buy rating for Neumora, while William Blair assigned a Hold rating on November 7.

    Tip Ranks·
    US
    NMRA
    +9.77%
    Tip Ranks·
    US
    NMRA
    +9.77%

    MapLight Therapeutics, Gold Royalty, and More Stocks See Action From Activist Investors

    Activists also report to the SEC on Neumora Therapeutics, Insight Enterprises, Garrett Motion, and Rogers.

    MSN·
    US
    RMCO
    -7.99%
    US
    NSIT
    +0.25%
    US
    NMRA
    +9.77%
    MSN·
    US
    RMCO
    -7.99%
    US
    NSIT
    +0.25%
    US
    NMRA
    +9.77%

    Neumora Therapeutics shares are trading lower after the company reported worse-than-expected Q3 EPS results.

    benzinga_article·
    US
    NMRA
    +9.77%
    benzinga_article·
    US
    NMRA
    +9.77%

    Neumora Therapeutics Unveils Pipeline Advancements Targeting Major Brain Disorders

    Neumora Therapeutics Inc. has unveiled its advancements in neuroscience drug development, focusing on major brain disorders such as depression, Alzheimer's agitation, schizophrenia, obesity, Parkinson's disease, and ALS. Key programs include Navacaprant for depression, NMRA-511 for Alzheimer's agitation, and two M4 modulators for schizophrenia. The pipeline also includes NMRA-215 for obesity and Parkinson's disease, with several clinical milestones anticipated in the coming year. The full corporate presentation is available online.

    Reuters·
    US
    NMRA
    +9.77%
    Reuters·
    US
    NMRA
    +9.77%

    Neumora Therapeutics | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    NMRA
    +9.77%
    LB filings·
    US
    NMRA
    +9.77%